| Literature DB >> 23667204 |
Jaffer A Ajani1, David J Bentrem, Stephen Besh, Thomas A D'Amico, Prajnan Das, Crystal Denlinger, Marwan G Fakih, Charles S Fuchs, Hans Gerdes, Robert E Glasgow, James A Hayman, Wayne L Hofstetter, David H Ilson, Rajesh N Keswani, Lawrence R Kleinberg, W Michael Korn, A Craig Lockhart, Kenneth Meredith, Mary F Mulcahy, Mark B Orringer, James A Posey, Aaron R Sasson, Walter J Scott, Vivian E Strong, Thomas K Varghese, Graham Warren, Mary Kay Washington, Christopher Willett, Cameron D Wright, Nicole R McMillian, Hema Sundar.
Abstract
The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence- and consensus-based recommendations for a multidisciplinary approach for the management of patients with gastric cancer. For patients with resectable locoregional cancer, the guidelines recommend gastrectomy with a D1+ or a modified D2 lymph node dissection (performed by experienced surgeons in high-volume centers). Postoperative chemoradiation is the preferred option after complete gastric resection for patients with T3-T4 tumors and node-positive T1-T2 tumors. Postoperative chemotherapy is included as an option after a modified D2 lymph node dissection for this group of patients. Trastuzumab with chemotherapy is recommended as first-line therapy for patients with HER2-positive advanced or metastatic cancer, confirmed by immunohistochemistry and, if needed, by fluorescence in situ hybridization for IHC 2+.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23667204 DOI： 10.6004/jnccn.2013.0070
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908